Introduction: Concentration of urinary cell-free DNA (ucfDNA) belongs to potential bladder cancer markers, but the reported results are inconsistent due to the use of various non-standardised methodologies. The aim of the study was to standardise the methodology for ucfDNA quantification as a potential non-invasive tumour biomarker. Material and Methods: In total, 66 patients and 34 controls were enrolled into the study. Volumes of each urine portion (V) were recorded and ucfDNA concentrations (c) were measured using real-time PCR. Total amounts (TA) of ucfDNA were calculated and compared between patients and controls. Diagnostic accuracy of the TA of ucfDNA was determined. Results: The calculation of TA of ucfDNA in the second urine portion was the most appropriate approach to ucfDNA quantification, as there was logarithmic dependence between the volume and the concentration of a urine portion (p = 0.0001). Using this methodology, we were able to discriminate between bladder cancer patients and subjects without bladder tumours (p = 0.0002) with area under the ROC curve of 0.725. Positive and negative predictive value of the test was 90 and 45%, respectively. Conclusion: Quantification of ucf DNA according to our modified method could provide a potential non-invasive biomarker for diagnosis of patients with bladder cancer.

Keywords:
Cell-free DNA, Urinary marker, Bladder cancer, Real-time PCR
1.
Larré S, et al: Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol 2013;63:1049-1058.
2.
Saad A, et al: A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002;89:369-373.
3.
Soukup V: Panel of urinary diagnostic markers for non-invasive detection of primary and recurrent urothelial urinary bladder carcinoma. Urol Int 2015, Epub ahead of print.
4.
Schmitz-Dräger BJ, et al: Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int 2015;94:1-24.
5.
Mandel P, Metais P: Les acides du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948;142:241-243.
6.
Esposito A, et al: Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. Cancer Treat Rev 2014;40:648-655.
7.
Antonatos D, et al: Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann N Y Acad Sci 2006;1075:278-281.
8.
García Moreira V, et al: Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. Clin Chem 2009;55:1958-1966.
9.
Hauser S, et al: Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study. Anticancer Res 2013;33:4651-4656.
10.
Ellinger J, et al: Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J Urol 2008;179:346-352.
11.
Hauser S, et al: Cell-free serum DNA in patients with bladder cancer: results of a prospective multicenter study. Anticancer Res 2012;32:3119-3124.
12.
Jung K, Fleischhacker M, Rabien A: Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clin Chim Acta 2010;411:1611-1624.
13.
Wang BG, et al: Increased plasma DNA integrity in cancer patients. Cancer Res 2003;63:3966-3968.
14.
Casadio V, et al: Urine cell-free DNA integrity as a marker for early bladder cancer diagnosis: preliminary data. Urol Oncol 2013;31:1744-1750.
15.
Zancan M, et al: Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. Int J Biol Markers 2009;24:147-155.
16.
Chang HW, et al: Urinary cell-free DNA as a potential tumor marker for bladder cancer. Int J Biol Markers 2007;22:287-294.
17.
Zancan M, et al: Free DNA in urine: a new marker for bladder cancer? Preliminary data. Int J Biol Markers 2005;20:134-136.
18.
Cannas A, et al: Implications of storing urinary DNA from different populations for molecular analyses. PLoS One 2009;4:e6985.
19.
Dyer AR, et al: Evaluation of measures of urinary albumin excretion in epidemiologic studies. Am J Epidemiol 2004;160:1122-1131.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.